Advertisement

Influence of Respiratory Syncytial Virus Strain Differences on Pathogenesis and Immunity

  • José A. Melero
  • Martin L. Moore
Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 372)

Abstract

Molecular epidemiology studies have provided convincing evidence of antigenic and sequence variability among respiratory syncytial virus (RSV) isolates. Circulating viruses have been classified into two antigenic groups (A and B) that correlate with well-delineated genetic groups. Most sequence and antigenic differences (both inter- and intra-groups) accumulate in two hypervariable segments of the G-protein gene. Sequences of the G gene have been used for phylogenetic analyses. These studies have shown a worldwide distribution of RSV strains with both local and global replacement of dominant viruses with time. Although data are still limited, there is evidence that strain variation may contribute to differences in pathogenicity. In addition, there is some but limited evidence that RSV variation may be, at least partially, immune (antibody) driven. However, there is the paradox in RSV that, in contrast to other viruses (e.g., influenza viruses) the epitopes recognized by the most effective RSV-neutralizing antibodies are highly conserved. In contrast, antibodies that recognize strain-specific epitopes are poorly neutralizing. It is likely that this apparent contradiction is due to the lack of a comprehensive knowledge of the duration and specificities of the human antibody response against RSV antigens. Since there are some data supporting a group- (or clade-) specific antibody response after a primary infection in humans, it may be wise to consider the incorporation of strains representative of groups A and B (or their antigens) in future RSV vaccine development.

Keywords

Respiratory Syncytial Virus Respiratory Syncytial Virus Infection Human Respiratory Syncytial Virus Respiratory Syncytial Virus Disease Immune Selection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Work in the Madrid laboratory is currently funded by grants GR09/0039 from Instituto de Salud Carlos III and SAF2009-11632 and SAF2012-31217 from Plan Nacional de I+D+i. Work in the Atlanta laboratory is supported by the following grants: NIH 1R01AI087798 and NIH 1U19AI095227.

References

  1. Agoti CN, Mwihuri AG, Sande CJ, Onyango CO, Medley GF, Cane PA, Nokes DJ (2012) Genetic relatedness of infecting and reinfecting respiratory syncytial virus strains identified in a birth cohort from rural Kenya. J Infect Dis 206:1532–1541PubMedCrossRefGoogle Scholar
  2. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K (1985) Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 151:623–633Google Scholar
  3. Anderson LJ, Bingham P, Hierholzer JC (1988) Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 62:4232–4238PubMedCentralPubMedGoogle Scholar
  4. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, Melero JA (1992) Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 73(Pt 9):2225–2234PubMedCrossRefGoogle Scholar
  5. Arnott A, Vong S, Mardy S, Chu S, Naughtin M, Sovann L, Buecher C, Beaute J, Rith S, Borand L, Asgari N, Frutos R, Guillard B, Touch S, Deubel V, Buchy P (2011) A study of the genetic variability of human respiratory syncytial virus (HRSV) in Cambodia reveals the existence of a new HRSV group B genotype. J Clin Microbiol 49:3504–3513PubMedCentralPubMedCrossRefGoogle Scholar
  6. Baek YH, Choi EH, Song MS, Pascua PN, Kwon HI, Park SJ, Lee JH, Woo SI, Ahn BH, Han HS, Hahn YS, Shin KS, Jang HL, Kim SY, Choi YK (2012) Prevalence and genetic characterization of respiratory syncytial virus (RSV) in hospitalized children in Korea. Arch Virol 157:1039–1050PubMedCrossRefGoogle Scholar
  7. Beeler JA, Van Wyke CK (1989) Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63:2941–2950PubMedCentralPubMedGoogle Scholar
  8. Beem M (1967) Repeated infections with respiratory syncytial virus. J Immunol 98:1115–1122PubMedGoogle Scholar
  9. Botosso VF, Zanotto PM, Ueda M, Arruda E, Gilio AE, Vieira SE, Stewien KE, Peret TC, Jamal LF, Pardini MI, Pinho JR, Massad E, Sant’anna OA, Holmes EC, Durigon EL (2009) Positive selection results in frequent reversible amino acid replacements in the G protein gene of human respiratory syncytial virus. PLoS Pathog 5:e1000254PubMedCentralPubMedCrossRefGoogle Scholar
  10. Buraphacheep W, Sullender WM (1997) The guinea pig as a model for the study of maternal immunization against respiratory syncytial virus infections in infancy. J Infect Dis 175:935–938PubMedCrossRefGoogle Scholar
  11. Cane PA, Pringle CR (1991) Respiratory syncytial virus heterogeneity during an epidemic: analysis by limited nucleotide sequencing (SH gene) and restriction mapping (N gene). J Gen Virol 72(Pt 2):349–357PubMedCrossRefGoogle Scholar
  12. Cane PA, Pringle CR (1995) Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein. J Virol 69:2918–2925PubMedCentralPubMedGoogle Scholar
  13. Cane PA, Thomas HM, Simpson AF, Evans JE, Hart CA, Pringle CR (1996) Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. J Med Virol 48:253–261PubMedCrossRefGoogle Scholar
  14. Cannon MJ, Stott EJ, Taylor G, Askonas BA (1987) Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology 62:133–138PubMedGoogle Scholar
  15. Cavallaro JJ, Maassab HF (1966) Adaptation of respiratory syncytial (RS) virus to brain of suckling mice. Proc Soc Exp Biol Med 121:37–41PubMedCrossRefGoogle Scholar
  16. Coates HV, Alling DW, Chanock RM (1966) An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 83:299–313PubMedGoogle Scholar
  17. Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM (2009) Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol 183:6338–6345PubMedCrossRefGoogle Scholar
  18. Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P (2007) A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog 3:1414–1421PubMedGoogle Scholar
  19. Connors M, Collins PL, Firestone CY, Murphy BR (1991) Respiratory syncytial virus (RSV) F, G, M2 (22 K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 65:1634–1637PubMedCentralPubMedGoogle Scholar
  20. Connors M, Kulkarni AB, Collins PL, Firestone CY, Holmes KL, Morse HC III, Murphy BR (1992) Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J Virol 66:1277–1281PubMedCentralPubMedGoogle Scholar
  21. Corbeil S, Seguin C, Trudel M (1996) Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine 14:521–525PubMedCrossRefGoogle Scholar
  22. Crowe JE, Firestone CY, Crim R, Beeler JA, Coelingh KL, Barbas CF, Burton DR, Chanock RM, Murphy BR (1998) Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology 252:373–375PubMedCrossRefGoogle Scholar
  23. Crowe JE Jr, Firestone CY, Murphy BR (2001) Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 167:3910–3918PubMedGoogle Scholar
  24. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:34–41PubMedCentralPubMedCrossRefGoogle Scholar
  25. Falsey AR, Walsh EE (1992) Humoral immunity to respiratory syncytial virus infection in the elderly. J Med Virol 36:39–43PubMedCrossRefGoogle Scholar
  26. Falsey AR, Walsh EE (1998) Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 177:463–466PubMedCrossRefGoogle Scholar
  27. Fisher RG, Johnson JE, Dillon SB, Parker RA, Graham BS (1999) Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. J Infect Dis 180:708–713PubMedCrossRefGoogle Scholar
  28. Fitch WM, Leiter JM, Li XQ, Palese P (1991) Positive Darwinian evolution in human influenza A viruses. Proc Natl Acad Sci U S A 88:4270–4274PubMedCentralPubMedCrossRefGoogle Scholar
  29. Garcia O, Martin M, Dopazo J, Arbiza J, Frabasile S, Russi J, Hortal M, Perez-Brena P, Martinez I, Garcia-Barreno B (1994) Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol 68:5448–5459PubMedCentralPubMedGoogle Scholar
  30. Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA (1989) Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 63:925–932PubMedCentralPubMedGoogle Scholar
  31. Garcia-Barreno B, Portela A, Delgado T, Lopez JA, Melero JA (1990) Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. EMBO J 9:4181–4187PubMedGoogle Scholar
  32. Gaunt ER, Jansen RR, Poovorawan Y, Templeton KE, Toms GL, Simmonds P (2011) Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus. PLoS ONE 6:e17427PubMedCentralPubMedCrossRefGoogle Scholar
  33. Gilca R, De Serres G, Tremblay M, Vachon ML, Leblanc E, Bergeron MG, Dery P, Boivin G (2006) Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis 193:54–58PubMedCrossRefGoogle Scholar
  34. Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:543–546PubMedGoogle Scholar
  35. Graham BS, Bunton LA, Wright PF, Karzon DT (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88:1026–1033PubMedCentralPubMedCrossRefGoogle Scholar
  36. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 329:1524–1530PubMedCrossRefGoogle Scholar
  37. Hall CB, Powell KR, Macdonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ (1986) Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 315:77–81PubMedCrossRefGoogle Scholar
  38. Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM, Hildreth SW, Anderson LJ (1990) Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 162:1283–1290PubMedCrossRefGoogle Scholar
  39. Hall CB, Walsh EE, Long CE, Schnabel KC (1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163:693–698PubMedCrossRefGoogle Scholar
  40. Heidema J, Lukens MV, van Maren WW, van Dijk ME, Otten HG, van Vught AJ, van der Werff DB, van Gestel SJ, Semple MG, Smyth RL, Kimpen JL, van Bleek GM (2007) CD8 + T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J Immunol 179:8410–8417PubMedGoogle Scholar
  41. Hemming VG, Prince GA (1990) Immunoprophylaxis of infections with respiratory syncytial virus: observations and hypothesis. Rev Infect Dis 12:S470–S475PubMedCrossRefGoogle Scholar
  42. Hendry RM, Burns JC, Walsh EE, Graham BS, Wright PF, Hemming VG, Rodriguez WJ, Kim HW, Prince GA, McIntosh K (1988) Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis 157:640–647PubMedCrossRefGoogle Scholar
  43. Johnson PR, Collins PL (1988) The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol 69(Pt 10):2623–2628PubMedCrossRefGoogle Scholar
  44. Johnson PR, Olmsted RA, Prince GA, Murphy BR, Alling DW, Walsh EE, Collins PL (1987a) Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 61:3163–3166PubMedCentralPubMedGoogle Scholar
  45. Johnson PR, Spriggs MK, Olmsted RA, Collins PL (1987b) The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A 84:5625–5629PubMedCentralPubMedCrossRefGoogle Scholar
  46. Jones LP, Zheng HQ, Karron RA, Peret TC, Tsou C, Anderson LJ (2002) Multiplex assay for detection of strain-specific antibodies against the two variable regions of the G protein of respiratory syncytial virus. Clin Diagn Lab Immunol 9:633–638PubMedCentralPubMedGoogle Scholar
  47. Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS (1997) Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A 94:13961–13966PubMedCentralPubMedCrossRefGoogle Scholar
  48. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422–434PubMedGoogle Scholar
  49. Knossow M, Skehel JJ (2006) Variation and infectivity neutralization in influenza. Immunology 119:1–7PubMedCrossRefGoogle Scholar
  50. Kuroiwa Y, Nagai K, Okita L, Yui I, Kase T, Nakayama T, Tsutsumi H (2005) A phylogenetic study of human respiratory syncytial viruses group A and B strains isolated in two cities in Japan from 1980–2002. J Med Virol 76:241–247PubMedCrossRefGoogle Scholar
  51. Lopez JA, Bustos R, Orvell C, Berois M, Arbiza J, Garcia-Barreno B, Melero JA (1998) Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 72:6922–6928PubMedCentralPubMedGoogle Scholar
  52. Lukacs NW, Moore ML, Rudd BD, Berlin AA, Collins RD, Olson SJ, Ho SB, Peebles RS Jr (2006) Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol 169:977–986PubMedCrossRefGoogle Scholar
  53. Magro M, Andreu D, Gomez-Puertas P, Melero JA, Palomo C (2010) Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol 84:7970–7982PubMedCentralPubMedCrossRefGoogle Scholar
  54. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, Terron MC, Melero JA, Palomo C (2012) Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 109:3089–3094PubMedCentralPubMedCrossRefGoogle Scholar
  55. Martinello RA, Chen MD, Weibel C, Kahn JS (2002) Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis 186:839–842PubMedCrossRefGoogle Scholar
  56. Martinez I, Melero JA (1998) Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J Gen Virol 79(Pt 9):2215–2220PubMedGoogle Scholar
  57. Martinez I, Dopazo J, Melero JA (1997) Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78(Pt 10):2419–2429PubMedGoogle Scholar
  58. Matheson JW, Rich FJ, Cohet C, Grimwood K, Huang QS, Penny D, Hendy MD, Kirman JR (2006) Distinct patterns of evolution between respiratory syncytial virus subgroups A and B from New Zealand isolates collected over thirty-seven years. J Med Virol 78:1354–1364PubMedCrossRefGoogle Scholar
  59. Mazzulli T, Peret TC, McGeer A, Cann D, MacDonald KS, Chua R, Erdman DD, Anderson LJ (1999) Molecular characterization of a nosocomial outbreak of human respiratory syncytial virus on an adult leukemia/lymphoma ward. J Infect Dis 180:1686–1689PubMedCrossRefGoogle Scholar
  60. Melero JA, Garcia-Barreno B, Martinez I, Pringle CR, Cane PA (1997) Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol 78(Pt 10):2411–2418PubMedGoogle Scholar
  61. Moore ML, Peebles RS Jr (2006) Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics. Pharmacol Ther 112:405–424PubMedCrossRefGoogle Scholar
  62. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE Jr, Goleniewska K, Williams JV, Collins PL, Peebles RS Jr (2009) A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83:4185–4194PubMedCentralPubMedCrossRefGoogle Scholar
  63. Muelenaer PM, Henderson FW, Hemming VG, Walsh EE, Anderson LJ, Prince GA, Murphy BR (1991) Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis 164:15–21PubMedCrossRefGoogle Scholar
  64. Mufson MA, Orvell C, Rafnar B, Norrby E (1985) Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 66(Pt 10):2111–2124PubMedCrossRefGoogle Scholar
  65. Murata Y, Lightfoote PM, Biear JN, Falsey AR, Walsh EE (2010a) Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein. Vaccine 28:6242–6246PubMedCentralPubMedCrossRefGoogle Scholar
  66. Murata Y, Lightfoote PM, Falsey AR, Walsh EE (2010b) Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein. Clin Vaccine Immunol 17:695–697PubMedCentralPubMedCrossRefGoogle Scholar
  67. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA (1988) Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol 62:3907–3910PubMedCentralPubMedGoogle Scholar
  68. Murphy BR, Prince GA, Collins PL, Hildreth SW, Paradiso PR (1991) Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV). Vaccine 9:185–189PubMedCrossRefGoogle Scholar
  69. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL (1986) Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A 83:7462–7466PubMedCentralPubMedCrossRefGoogle Scholar
  70. Palomo C, Cane PA, Melero JA (2000) Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains. J Med Virol 60:468–474PubMedCrossRefGoogle Scholar
  71. Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ (1998) Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 79(Pt 9):2221–2229PubMedGoogle Scholar
  72. Peret TC, Hall CB, Hammond GW, Piedra PA, Storch GA, Sullender WM, Tsou C, Anderson LJ (2000) Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis 181:1891–1896PubMedCrossRefGoogle Scholar
  73. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, Kleeberger SR, Wills-Karp M, Karron RA (2002) A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196:859–865PubMedCentralPubMedCrossRefGoogle Scholar
  74. Prince GA, Porter DD (1975) The pathogenesis of respiratory syncytial virus infection in infant ferrets. Am J Pathol 82:339–352Google Scholar
  75. Prince GA, Horswood RL, Camargo E, Koenig D, Chanock RM (1983) Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun 42:81–87PubMedCentralPubMedGoogle Scholar
  76. Prince GA, Horswood RL, Chanock RM (1985) Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55:517–520PubMedCentralPubMedGoogle Scholar
  77. Reiche J, Schweiger B (2009) Genetic variability of group A human respiratory syncytial virus strains circulating in Germany from 1998 to 2007. J Clin Microbiol 47:1800–1810PubMedCentralPubMedCrossRefGoogle Scholar
  78. Rueda P, Delgado T, Portela A, Melero JA, Garcia-Barreno B (1991) Premature stop codons in the G glycoprotein of human respiratory syncytial viruses resistant to neutralization by monoclonal antibodies. J Virol 65:3374–3378PubMedCentralPubMedGoogle Scholar
  79. Rueda P, Garcia-Barreno B, Melero JA (1994) Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple A-G substitutions (hypermutations). Virology 198:653–662PubMedCrossRefGoogle Scholar
  80. Rueda P, Palomo C, Garcia-Barreno B, Melero JA (1995) The three C-terminal residues of human respiratory syncytial virus G glycoprotein (Long strain) are essential for integrity of multiple epitopes distinguishable by antiidiotypic antibodies. Viral Immunol 8:37–46PubMedCrossRefGoogle Scholar
  81. Sastre P (2004) Caracterización de anticuerpos dirigidos frente al virus respiratorio sincitial humano presentes en preparaciones de inmunoglobulinas humanas. PhD ThesisGoogle Scholar
  82. Sastre P, Melero JA, Garcia-Barreno B, Palomo C (2004) Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities. Vaccine 23:435–443PubMedCrossRefGoogle Scholar
  83. Scott PD, Ochola R, Ngama M, Okiro EA, Nokes DJ, Medley GF, Cane PA (2004) Molecular epidemiology of respiratory syncytial virus in Kilifi district, Kenya. J Med Virol 74:344–354PubMedCrossRefGoogle Scholar
  84. Scott PD, Ochola R, Sande C, Ngama M, Okiro EA, Medley GF, Nokes DJ, Cane PA (2007) Comparison of strain-specific antibody responses during primary and secondary infections with respiratory syncytial virus. J Med Virol 79:1943–1950PubMedCrossRefGoogle Scholar
  85. Shobugawa Y, Saito R, Sano Y, Zaraket H, Suzuki Y, Kumaki A, Dapat I, Oguma T, Yamaguchi M, Suzuki H (2009) Emerging genotypes of human respiratory syncytial virus subgroup A among patients in Japan. J Clin Microbiol 47:2475–2482PubMedCentralPubMedCrossRefGoogle Scholar
  86. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, Hotard A, Sherrill TP, Peebles RS Jr, Moore ML (2011) Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 85:5782–5793PubMedCentralPubMedCrossRefGoogle Scholar
  87. Stott EJ, Ball LA, Young KK, Furze J, Wertz GW (1986) Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol 60:607–613PubMedCentralPubMedGoogle Scholar
  88. Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, Wertz GW (1987) Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 61:3855–3861PubMedCentralPubMedGoogle Scholar
  89. Suto T, Yano N, Ikeda M, Miyamoto M, Takai S, Shigeta S, Hinuma Y, Ishida N (1965) Respiratory syncytial virus infection and its serologic epidemiology. Am J Epidemiol 82:211–224PubMedGoogle Scholar
  90. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731–2739PubMedCrossRefGoogle Scholar
  91. Taylor G, Stott EJ, Bew M, Fernie BF, Cote PJ, Collins AP, Hughes M, Jebbett J (1984) Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:137–142PubMedGoogle Scholar
  92. Taylor GS, Vipond IB, Caul EO (2001) Molecular epidemiology of outbreak of respiratory syncytial virus within bone marrow transplantation unit. J Clin Microbiol 39:801–803PubMedCentralPubMedCrossRefGoogle Scholar
  93. Tome L, Frabasile S, Candia C, Pittini A, Farina N, Melero JA, Arbiza J (2012) Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein. Arch Virol 157(6):1071–1080Google Scholar
  94. Trento A, Galiano M, Videla C, Carballal G, Garcia-Barreno B, Melero JA, Palomo C (2003) Major changes in the G protein of human respiratory syncytial virus isolates introduced by a duplication of 60 nucleotides. J Gen Virol 84:3115–3120PubMedCrossRefGoogle Scholar
  95. Trento A, Viegas M, Galiano M, Videla C, Carballal G, Mistchenko AS, Melero JA (2006) Natural history of human respiratory syncytial virus inferred from phylogenetic analysis of the attachment (G) glycoprotein with a 60-nucleotide duplication. J Virol 80:975–984PubMedCentralPubMedCrossRefGoogle Scholar
  96. Trento A, Casas I, Calderon A, Garcia-Garcia ML, Calvo C, Perez-Brena P, Melero JA (2010) Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. J Virol 84:7500–7512PubMedCentralPubMedCrossRefGoogle Scholar
  97. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, Garcia-Sastre A (2005) Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310:77–80PubMedCrossRefGoogle Scholar
  98. Venter M, Madhi SA, Tiemessen CT, Schoub BD (2001) Genetic diversity and molecular epidemiology of respiratory syncytial virus over four consecutive seasons in South Africa: identification of new subgroup A and B genotypes. J Gen Virol 82:2117–2124PubMedGoogle Scholar
  99. Venter M, Collinson M, Schoub BD (2002) Molecular epidemiological analysis of community circulating respiratory syncytial virus in rural South Africa: comparison of viruses and genotypes responsible for different disease manifestations. J Med Virol 68:452–461PubMedCrossRefGoogle Scholar
  100. Viegas M, Mistchenko AS (2005) Molecular epidemiology of human respiratory syncytial virus subgroup A over a six-year period (1999–2004) in Argentina. J Med Virol 77:302–310PubMedCrossRefGoogle Scholar
  101. Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF (2012) In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci U S A 109:5040–5045PubMedCentralPubMedCrossRefGoogle Scholar
  102. Walsh EE, Schlesinger JJ, Brandriss MW (1984) Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 43:756–758PubMedCentralPubMedGoogle Scholar
  103. Walsh EE, Falsey AR, Sullender WM (1998) Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein. J Gen Virol 79(Pt 3):479–487PubMedGoogle Scholar
  104. Wertz GW, Stott EJ, Young KK, Anderson K, Ball LA (1987) Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol 61:293–301PubMedCentralPubMedGoogle Scholar
  105. Woelk CH, Holmes EC (2001) Variable immune-driven natural selection in the attachment (G) glycoprotein of respiratory syncytial virus (RSV). J Mol Evol 52:182–192PubMedGoogle Scholar
  106. Yamaguchi M, Sano Y, Dapat IC, Saito R, Suzuki Y, Kumaki A, Shobugawa Y, Dapat C, Uchiyama M, Suzuki H (2011) High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan. J Clin Microbiol 49:1034–1040PubMedCentralPubMedCrossRefGoogle Scholar
  107. Zhang Y, Xu W, Shen K, Xie Z, Sun L, Lu Q, Liu C, Liang G, Beeler JA, Anderson LJ (2007) Genetic variability of group A and B human respiratory syncytial viruses isolated from 3 provinces in China. Arch Virol 152:1425–1434PubMedCrossRefGoogle Scholar
  108. Zhang RF, Jin Y, Xie ZP, Liu N, Yan KL, Gao HC, Song JR, Yuan XH, Xiao NG, Guo MW, Zhou QH, Hou YD, Duan Z (2010a) Human respiratory syncytial virus in children with acute respiratory tract infections in China. J Clin Microbiol 48:4193–4199PubMedCentralPubMedCrossRefGoogle Scholar
  109. Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, Tripp RA (2010b) Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 84:1148–1157PubMedCentralPubMedCrossRefGoogle Scholar
  110. Zhang ZY, Du LN, Chen X, Zhao Y, Liu EM, Yang XQ, Zhao XD (2010c) Genetic variability of respiratory syncytial viruses (RSV) prevalent in Southwestern China from 2006 to 2009: emergence of subgroup B and A RSV as dominant strains. J Clin Microbiol 48:1201–1207PubMedCentralPubMedCrossRefGoogle Scholar
  111. Zhao X, Chen FP, Megaw AG, Sullender WM (2004a) Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 190:1941–1946PubMedCrossRefGoogle Scholar
  112. Zhao X, Chen FP, Sullender WM (2004b) Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318:608–612PubMedCrossRefGoogle Scholar
  113. Zlateva KT, Vijgen L, Dekeersmaeker N, Naranjo C, Van Ranst M (2007) Subgroup prevalence and genotype circulation patterns of human respiratory syncytial virus in Belgium during ten successive epidemic seasons. J Clin Microbiol 45:3022–3030PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Unidad de Biología Viral, Centro Nacional de MicrobiologíaInstituto de Salud Carlos IIIMadridSpain
  2. 2.Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES)Instituto de Salud Carlos IIIMadridSpain
  3. 3.Department of PediatricsEmory UniversityAtlantaUSA
  4. 4.Children’s Healthcare of AtlantaAtlantaUSA

Personalised recommendations